Analysis of the efficacy and safety of endoscopic retrograde cholangiopancreatography for the treatment of pediatric pancreatobiliary diseases.

Background: Traditional surgical procedures are highly invasive and risky for children with pancreatic and biliary diseases. Endoscopic retrograde cholangiopancreatography (ERCP) has been used mostly in adults because it is a safe and effective surgical procedure. Its application in children will contribute to the treatment and prognosis of children with pancreatic and biliary diseases.

Aim: To analyze the efficacy and safety of ERCP for the treatment of pediatric pancreatobiliary diseases.

Methods: A retrospective study was performed using the medical records of 101 pediatric patients who received treatment for pancreatobiliary diseases at Children's Hospital Capital Institute of Pediatrics from April 2022 to April 2024. The patients were divided into an observation group ( = 52, treated with ERCP) and a control group ( = 49, treated with traditional surgical methods). Diagnostic and therapeutic outcomes of ERCP were statistically analyzed. Treatment efficacy, time to resume eating, and hospital stay duration were compared between the two groups. Indicators of liver function were monitored preoperatively and one week postoperatively. Dynamic changes in C-reactive protein (CRP) and serum amylase levels were assessed preoperatively and at 6 and 24 hours postoperatively. Postoperative complications were also compared. Logistic multivariate regression was used to analyze the independent effect of ERCP on outcomes.

Results: For the observation group, 36 and 16 patients were diagnosed with biliary and pancreatic diseases, respectively. Compared with the control group, the observation group exhibited a higher overall effective rate ( < 0.05), shorter times to resume eating, shorter hospital stays ( < 0.05), and significantly improved postoperative liver function ( < 0.05). CRP and serum amylase levels were significantly increased in both groups at 6 and 24 hours postoperatively ( < 0.05), but were significantly lower in the observation group ( < 0.05). The observation group also had a lower incidence of complications ( < 0.05). ERCP was an independent factor affecting treatment efficacy, length of hospital stay, total bilirubin, aspartate aminotransferase, and alanine aminotransferase, CRP, serum amylase, and the occurrence of complications in children with pancreaticobiliary diseases ( < 0.05).

Conclusion: ERCP effectively enhances the treatment efficacy of pediatric pancreatobiliary diseases, with a reduced inflammatory response, faster postoperative recovery, and fewer complications. ERCP is a safe and effective diagnostic and therapeutic method for pediatric pancreatobiliary diseases.